Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

Interest Coverage 106.92
HITK's Interest Coverage is ranked higher than
51% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. HITK: 106.92 )
Ranked among companies with meaningful Interest Coverage only.
HITK' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 106.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» HITK's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

HITK Guru Trades in

HITK Guru Trades in

HITK Guru Trades in

Q2 2014

HITK Guru Trades in Q2 2014

Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HITK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Traded in other countries:HT6.Germany,

Hi-Tech Pharmacal Co., Inc. is incorporated in Delaware in 1982. The company is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. It develops, manufacture and market products in three categories namely generics, prescription brands and over the counter ('OTC') brands. It produce a wide range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. The generic product category includes a small amount of contract manufacturing sales for both the prescription and OTC markets. Its Health Care Products Division ('HCP') markets a line of OTC branded products for people with diabetes, including Diabetic Tussin , DiabetiDerm, Multi-betic, Mag-Ox, Choice DM and DiabetiSweet. The division also sells the Zostrix brand of capsaicin products for pain management of conditions including arthritis and foot pain. In addition, HCP markets Nasal Ease homeopathic allergy reliever and the recently acquired Sinus Buster brand homeopathic sinus congestion reliever. Its ECR Pharmaceuticals ('ECR Pharmaceuticals' or 'ECR') subsidiary is engaged in the marketing and distribution of branded prescription pharmaceuticals. ECR's products treat various disease states, including tension headache, pain, cough/cold and allergies, contact dermatitis, wound care, sleep disorders and swimmer's ear. Its customers include chain drug stores, drug wholesalers, and managed care purchasing organizations, certain Federal government agencies, generic distributors, mass merchandisers, and mail-order pharmacies. Some of its key customers include McKesson Corporation, Walgreens, Cardinal Health, Inc., AmeriSourceBergen Corporation, CVS and Medco. The company has 55 prescription products approved for marketing by the U.S. Food and Drug Administration ('FDA') and one product with tentative approval. In addition, it has 18 products submitted to the FDA pending approval, including one product, mesalamine, filed by another company in which the Company has approximately a 45% financial interest and approximately 25 products in various stages of development. Its products and facilities are subject to regulation by a number of Federal and state governmental agencies.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $227.5
EPS (TTM) $ 0.66
Short Percentage of Float20.55%
52-Week Range $29.24 - 44.33
Shares Outstanding (Mil)13.58

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)